GABAergic signaling by AgRP neurons prevents anorexia via a melanocortin-independent mechanism
Abubakar M, Nama L, Ansari MA, Ansari MM, Bhardwaj S, Daksh R, Syamala KLV, Jamadade MS, Chhabra V, Kumar D, Kumar N (2024) GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimers Disease through its Supporting DPP4 Inhibitors: A Review
45,46 These results were confirmed by a pooled analysis that demonstrated that the improvement in quality of life and functional capacity may be primarily related to weight loss, and that there were significant declines in HF hospitalisations or urgent visits (8 [1%] versus 30 [5%] patients in the semaglutide and placebo groups, respectively
The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation
0,2 aos en pacientes diabticos con factores de riesgo cardiovascular nicamente, sugiriendo un beneficio adicional de semaglutida en esta poblacin de alto riesgo cardiovascular88
The ATTAIN-1 trial enrolled 3,127 participants and compared three doses of orforglipron (6, 12 and 36 mg) with placebo over 72 weeks